Korbut R, Gryglewski R J
Department of Pharmacology, Medical College of Jagiellonian University, Cracow, Poland.
J Physiol Pharmacol. 1996 Dec;47(4):591-9.
Six hours after administration of E. Coli endotoxin (LPS) into rats (10 mg kg-1, i.p.) a significant (P < 0.001) decline in the red blood cell deformability index (RBC Dj) was observed. The control Di value of untreated animals it was 300 +/- 39 RBC x 10(6)/min (means +/- S.D.; n = 12) while in LPS treated animals was 140 +/- 50 RBC x 10(6)/min; n = 12. Pretreatment of the animals with the stable analogue of prostacyclin, iloprost (30 micrograms/kg, i.p.) or with the inhibitor of thromboxane A2-synthase, camonagrel (10 mg/kg, i.p.), but not with nitric oxide donor, such as GEA 5285 (10 mg/kg, i.p.), significantly increased deformability of red blood cells in the group of non-septicaemic animals, and antagonized the LPS-induced decline in red blood cell deformability of septicaemic rats. Administration of NG-nitro-L-arginine (L-NNA, 30 mg/kg, i.p.), as that of aspirin (50 mg/kg, i.p.), did not affect red blood cell deformability in non-septicaemic rats, however, in contrast with aspirin, it significantly improved deformability of red blood cells in LPS-treated animals. It is concluded that prostacyclin, camonagrel and L-NNA can act as protective agents against LPS-induced loss of red blood cell deformability. The mechanisms of this protection are complex and, possibly, related to the specific effects of these agents on biochemical function of leukocytes present in RBC suspension. While the effect of exogenous prostacyclin (iloprost) may be explained on the basis of its direct cytoprotective potency on leukocytes, the effect of camonagrel is indirect and can be attributed both to the release of endogenous prostacyclin and to the inhibition of thromboxane A2-synthase. The protection induced by NO-synthase inhibitor seems to depend upon inhibition of an increase of the generation of nitric oxide which follows administration of LPS.
给大鼠腹腔注射大肠杆菌内毒素(LPS,10毫克/千克)6小时后,观察到红细胞变形性指数(RBC Dj)显著下降(P < 0.001)。未处理动物的对照Di值为300 ± 39 RBC × 10⁶/分钟(平均值 ± 标准差;n = 12),而LPS处理动物的该值为140 ± 50 RBC × 10⁶/分钟;n = 12。用前列环素的稳定类似物伊洛前列素(30微克/千克,腹腔注射)或血栓素A2合酶抑制剂卡莫格雷(10毫克/千克,腹腔注射)对动物进行预处理,但用一氧化氮供体如GEA 5285(10毫克/千克,腹腔注射)则不能,可显著增加非败血症动物组红细胞的变形性,并拮抗LPS诱导的败血症大鼠红细胞变形性下降。腹腔注射NG-硝基-L-精氨酸(L-NNA,30毫克/千克),与阿司匹林(50毫克/千克,腹腔注射)一样,对非败血症大鼠的红细胞变形性无影响,然而,与阿司匹林不同的是,它显著改善了LPS处理动物的红细胞变形性。得出的结论是,前列环素、卡莫格雷和L-NNA可作为针对LPS诱导的红细胞变形性丧失的保护剂。这种保护机制很复杂,可能与这些药物对RBC悬液中存在的白细胞生化功能的特定作用有关。虽然外源性前列环素(伊洛前列素)的作用可基于其对白细胞的直接细胞保护作用来解释,但卡莫格雷的作用是间接的,可归因于内源性前列环素的释放和血栓素A2合酶的抑制。一氧化氮合酶抑制剂诱导的保护作用似乎取决于对LPS给药后一氧化氮生成增加的抑制。